Yuflyma 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0032 
Minor change in labelling or package leaflet not 
11/01/2024 
PL 
connected with the SPC (Art. 61.3 Notification) 
X/0022 
Annex I_2.(c) Change or addition of a new 
14/09/2023 
15/11/2023 
SmPC, 
strength/potency 
Labelling and 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
IB/0031 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/10/2023 
PL 
PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0030 
B.II.b.2.a - Change to importer, batch release 
07/09/2023 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0029 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
06/09/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
PSUSA/10783
Periodic Safety Update EU Single assessment - 
31/08/2023 
n/a 
PRAC Recommendation - maintenance 
/202212 
adalimumab 
IAIN/0028/G 
This was an application for a group of variations. 
17/07/2023 
15/11/2023 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
Page 2/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0027 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
28/04/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IA/0026 
A.5.b - Administrative change - Change in the name 
11/04/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0020/G 
This was an application for a group of variations. 
25/01/2023 
20/02/2023 
SmPC and PL 
Product information SmPC section 6.3 is updated to reflect 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
B.II.f.1.b.2 - Stability of FP - Extension of the shelf 
life of the finished product - After first opening 
(supported by real time data) 
IAIN/0023 
B.II.b.1.a - Replacement or addition of a 
20/01/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0021 
B.II.b.1.a - Replacement or addition of a 
13/01/2023 
n/a 
the shelf-life extension of the finished product Yuflyma 80 
mg/0.8 mL (EU/1/20/1513/013-015) as packaged for sale 
from 30 months to 3 years when stored at 2 - 8°C. Product 
information SmPC section 6.4 and PIL section 5 updated to 
reflect shelf-life extension of the finished product Yuflyma 
80 mg/0.8 mL after first opening from 30 days to 31 days 
when stored at 25 °C. 
Page 3/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Secondary packaging 
site 
IB/0019/G 
This was an application for a group of variations. 
31/08/2022 
n/a 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.b - Change in test procedure for the finished 
product - Deletion of a test procedure if an 
alternative method is already authorised 
IB/0018 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
28/07/2022 
20/02/2023 
SmPC, 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
Labelling and 
PL 
IB/0016 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
27/06/2022 
n/a 
Page 4/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IA/0017 
B.I.c.z - Container closure system of the AS - Other 
22/06/2022 
n/a 
variation 
IB/0015/G 
This was an application for a group of variations. 
13/06/2022 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
IA/0014/G 
This was an application for a group of variations. 
14/03/2022 
n/a 
B.I.c.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Addition of a new specification parameter to the 
specification with its corresponding test method 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
IB/0013 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
11/03/2022 
20/02/2023 
SmPC and PL 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IB/0012 
B.I.a.1.z - Change in the manufacturer of AS or of a 
03/03/2022 
n/a 
Page 5/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate for AS - Other 
variation 
IA/0011/G 
This was an application for a group of variations. 
18/02/2022 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
X/0005 
Extension application to introduce a new strengths of 
16/12/2021 
16/02/2022 
SmPC, 
Page 6/9 
 
 
 
 
 
 
 
 
 
 
 
80 mg solution for injection.  
Version 1.1 of the RMP has also been submitted. 
Labelling and 
PL 
Annex I_2.(c) Change or addition of a new 
strength/potency 
II/0009/G 
This was an application for a group of variations. 
20/01/2022 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.z - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Other variation 
B.II.b.2.b - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
IB/0010 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
01/12/2021 
16/02/2022 
SmPC and PL 
To extend the shelf-life of the finished product Yuflyma, 40 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
mg, Solution for Injection and include editorial changes in 
the PI and Annex A. 
Page 7/9 
 
 
 
 
 
 
 
 
 
 
 
stability protocol 
N/0008 
Minor change in labelling or package leaflet not 
11/10/2021 
16/02/2022 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IB/0007 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
13/07/2021 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
II/0002 
B.I.a.1.j - Change in the manufacturer of AS or of a 
01/07/2021 
n/a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
IAIN/0006/G 
This was an application for a group of variations. 
04/06/2021 
16/02/2022 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
29/04/2021 
19/05/2021 
SmPC, 
generic/hybrid/biosimilar products following 
Labelling and 
Page 8/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PL 
IAIN/0003 
C.I.z - Changes (Safety/Efficacy) of Human and 
06/04/2021 
19/05/2021 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IAIN/0001 
B.II.b.1.a - Replacement or addition of a 
24/03/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 9/9 
 
 
 
 
 
 
 
 
 
 
 
 
